Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.

Article Details

Citation
Copy to clipboard

Aprile G, Bonotto M, Ongaro E, Pozzo C, Giuliani F

Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.

Drugs. 2013 Dec;73(18):2003-15. doi: 10.1007/s40265-013-0154-8.

PubMed ID
24277700 [ View in PubMed
]
Abstract

Although antiangiogenic treatments have produced milestone advances in the treatment of several diseases, and have significantly extended the median survival of cancer patients, these agents share some weaknesses, including a limited impact on the overall cure rate, a fleeting effect because of redundant pathways or early appearance of resistance mechanisms, and the lack of predictive factors for treatment selection. Recent data suggest that antibodies targeting the vascular endothelial growth factor axis exert their activity through the inhibition of vascular endothelial growth factor receptor-2 phosphorylation, which has a pivotal role in the neoangiogenic process. Ramucirumab, a fully humanized monoclonal antibody specifically directed against the extracellular domain of the receptor, administered intravenously every 2 or 3 weeks, is emerging as a novel antiangiogenic opportunity. Starting with preclinical data and early clinical results, this concise review focuses on the development of the novel compound across multiple cancers (including gastrointestinal malignancies, breast cancer, lung carcinoma, and genitourinary tumors), and presents available data from randomized phase II and phase III trials. REGARD was the first phase III study to report on the efficacy of single-agent ramucirumab in patients with advanced cancer. Many other ongoing phase III trials are testing the efficacy of this interesting antiangiogenic compound as a single agent or in combination with chemotherapy in different cancer types.

DrugBank Data that Cites this Article

Drugs